about
Active surveillance and focal therapy for low-intermediate risk prostate cancerActive surveillance for prostate cancer: progress and promiseMaximal testosterone suppression in the management of recurrent and metastatic prostate cancerStandards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working GroupAppropriateness Criteria for Active Surveillance of Prostate Cancer.Realistic anatomical prostate models for surgical skills workshops using ballistic gelatin for nerve-sparing radical prostatectomy and fruit for simple prostatectomy.Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.What can surrogate tissues tell us about the oxidative stress status of the prostate? A hypothesis-generating in-vivo study.Using consensus guidelines effectivelyIntegrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.How (not) to communicate new scientific information: a memoir of the famous Brindley lecture.Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapyCombined androgen blockade: the case for bicalutamide.Combined androgen blockade: an update.The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancerActive surveillance for prostate cancer: a review.Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.Critical evaluation of hormonal therapy for carcinoma of the prostate.Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience.Intermittent androgen suppression in prostate cancer: the Canadian experience.Maximal testosterone suppression in prostate cancer--free vs total testosteronePhase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADTConservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?Dietary fat and prostate cancer.Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer.Active surveillance for the management of localized prostate cancer: Guideline recommendationsCanadian Consensus Conference: The FDA decision on the use of 5ARIs.Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.Active surveillance for low-risk prostate cancer.Active surveillance for prostate cancer: for whom?Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.Intermittent androgen suppression for rising PSA level after radiotherapy.Cardiovascular effects of androgen depletion and replacement therapy.
P50
Q26773641-EF3A3635-5325-4D48-99A0-5465415D454AQ28245173-2524C5AC-6574-4998-B724-083FA9AD45FCQ29994552-89F13480-21B3-40A3-8EE8-DE7D99FCF5F7Q30054617-CA53464D-0426-439E-8D77-B415CA772426Q30390608-9AE95B7C-7829-4F9A-9952-5F5F405DB969Q30498264-6E27168F-9F44-49E2-8157-BAA0C6CCCA84Q30736842-1300523F-7EC4-40CC-9488-850CBB7B4264Q30994599-7B856AD6-B633-4FC2-88D1-B6C0889FE210Q33613076-2C196DF4-ECE6-49FD-884D-A616EE3AF5F1Q33970755-6EE9F48D-1A7B-4063-98D6-C61C30218850Q33990695-9DDDA6A3-6AED-48FD-94F9-00AC45C30E1DQ34076949-C2A2D473-8822-4C14-B976-4E7102F4A156Q34156630-F1A5BCC5-B7A7-4611-9343-065F8F6C89F8Q34323815-A7C11715-CA0E-466D-87AF-DDED22918013Q34417170-D14CB18E-52CD-4A65-91A1-419B501C0B17Q34516418-A231D6D9-1E76-40B8-AA3C-1E9ACE37600DQ34600965-A59F6358-9192-44CF-BB0E-B02D2029BE39Q34617904-036B91AF-31C1-485F-AE18-763D97F64865Q34633492-48CD991E-FFAF-4907-B0BE-A0C8B13B7C73Q34636636-4278FD36-89E4-4755-90E7-4D0A86CBDAD1Q34758712-F929780D-7A57-4975-931B-9ECD402C7D0CQ34856489-1AE6A928-7047-4AE7-A36C-D2294CB226B7Q34856591-8087064B-EF5E-4DE9-BCE5-AD5BA461F830Q34856607-1151680E-9D10-48B1-873F-EA3123C7A927Q35096022-DC508ED7-BA52-44F5-AE21-51D9B405BB6CQ35187828-C1FBCA24-B5D5-4784-BA79-6F782F95B340Q35215038-DC5A84CC-4D45-40D5-A55F-5163010BAC0DQ35565196-132890EA-BD42-4052-9042-F9BEF5D64770Q35624790-FC4110F9-CC2A-4BFB-A8AB-B6B80A53414AQ35710025-163E231E-021D-4283-9E50-B76F46CF83C5Q35725546-A97B6089-740E-41D9-83AD-BDAEBA7B37CBQ35894624-A8586F92-8B77-40DE-90DB-E057E5164229Q35944492-1625FAC1-CF12-4464-BFA9-C8109C04F460Q35974780-EFCCC4E2-FAC0-4C60-8E9A-69982243B494Q36141777-0B9F3746-2CE5-4145-8BE6-27BFDCCE4AF2Q36309679-F2AAB7FD-1BBB-407C-BE2D-5A7A91B17073Q36356246-96A17715-AC07-4235-B6E0-2C4C6DDCD0A0Q36395126-933A08D0-471C-4FF6-BFD5-0DAABD1892C3Q36463238-9B662D59-34DA-4852-B871-607846A410A0Q36501994-4E478405-A981-40B7-BC5D-FDA1424BC191
P50
name
Laurence Klotz
@en
type
label
Laurence Klotz
@en
prefLabel
Laurence Klotz
@en